CAS number: 126740-76-9—Key glycosylation structural unit for glycopeptide research and treatment

As one of the most complex and critical post-translational modifications in living organisms, glycosylation deeply regulates core biological processes such as protein function, intercellular communication, and immune response. Among the many glycosylation structures, GlcNAc beta(1-3)GalNAc-alpha-Thr, as a typical O-linked glycopeptide fragment, is not only an important component of natural glycoproteins (such as mucin), but also an indispensable molecular tool in modern glycobiology research and glycopeptide drug design and development. Its unique chemical structure gives it the ability to mimic natural sugar epitopes, providing a solid foundation for the leap from basic science to clinical application.

Chemical Information

Chemical name: 2-acetylamino-2-deoxy-β-D-glucopyranosyl-(1→3)-2-acetylamino-2-deoxy-α-D-galactopyranosyl-threonine

Common name: GlcNAc beta(1-3)GalNAc-alpha-Thr

Chemical formula: C19H33N3O13

Molecular weight: 511.48 g/mol

CAS number: 126740-76-9

Category: Glycopeptides

Structural features

The structure of GlcNAc beta(1-3)GalNAc-alpha-Thr reflects the precise chemical assembly and biological specificity of the glycopeptide:

Specific glycosidic bond connection mode: The molecule is composed of two amino sugar units - N-acetylglucosamine (GlcNAc) is connected to N-acetylgalactosamine (GalNAc) through a β(1-3) glycosidic bond, while GalNAc is combined with the hydroxyl group of threonine (Thr) through an α-glycosidic bond. This combination of C1-O-C3' β-linkage and C1-O-Thr α-linkage forms a highly ordered sugar chain conformation, simulating the core skeleton of natural O-linked glycosylation.

Stereochemistry and conformational stability: The β(1-3) linkage gives the sugar chain a certain rigid stretch and reduces steric hindrance, while the α-linkage to Thr retains the stereochemical environment of the sugar-amino acid interface in natural glycopeptides. This structure enables the entire molecule to form stable folds or expose specific epitopes for high-affinity, high-specific interactions with proteins such as lectins, antibodies, or enzymes.

Enhanced hydrogen bond network and molecular recognition: The acetamido group and the hydroxyl group on the sugar ring provide abundant hydrogen bond donors and acceptors, which not only enhances water solubility, but also promotes precise binding to biological macromolecules. This property makes it an ideal model for studying sugar-protein interactions, which play a key role in cell surface receptor recognition and signal transduction.

Main applications and advantages

Core antigen design of glycopeptide vaccines and immunotherapy

Tumor-associated carbohydrate antigen simulation: In various cancers (such as breast cancer and pancreatic cancer), the GlcNAc beta(1-3)GalNAc structure is often abnormally highly expressed on mucins such as MUC1 and becomes a tumor-specific marker. By using this glycopeptide fragment to synthesize antigens, vaccines targeting these glycotopes can be developed to induce the body to produce specific antibodies and T cell responses, providing a new strategy for cancer immunotherapy.

Immunogenicity optimization: Compared with simple sugar chains, this glycopeptide conjugate more completely simulates the local structure of natural glycoproteins, helping to break through immune tolerance and improve the intensity and specificity of immune responses. At the same time, its stable structure can reduce degradation, extend the half-life in the body, and enhance vaccine effectiveness.

An important tool for glycobiology and enzymology research

Glycosyltransferase and glycosidase analysis: As natural substrate analogs of these enzymes, it is used to explore the biosynthetic pathway, enzymatic reaction mechanism and substrate specificity of O-linked glycosylation. This is of great value in glycoengineering and drug target discovery, such as the development of inhibitors against aberrant glycosylation diseases.

Analysis of cell recognition mechanism: This structure is widely involved in processes such as cell adhesion, pathogen infection, and inflammatory response. By integrating it into probes or chips, sugar-receptor interactions can be monitored in real time, revealing the molecular basis of relevant diseases, such as cancer metastasis or autoimmune disorders.

Diagnostic reagents and biomarker development

Disease status monitoring: O-linked glycosylation patterns are significantly altered under a variety of pathological conditions (e.g., malignancy, chronic inflammation). GlcNAc beta(1-3)GalNAc-alpha-Thr can be used as a standard or capture molecule to develop highly sensitive detection methods (such as ELISA or mass spectrometry analysis) to achieve early diagnosis or efficacy evaluation.

Personalized medical applications: Combining genomics and proteomics data, this glycopeptide helps to establish a database of associations between glycosylation profiles and diseases, promoting the development of precision medicine.

Precursors for the synthesis of glycoproteins and biomaterials

Chemoenzymatic synthesis of glycoconjugates: as modular building blocks for the stepwise assembly of complex glycoproteins or glycopolymers, advancing the field of synthetic glycobiology. For example, uniform sugar-modified protein drugs can be prepared through solid-phase synthesis or enzyme-catalyzed coupling to improve their pharmacokinetic properties.

Biointerface functionalization: Modifying such glycopeptides onto the surface of nanoparticles, hydrogels or implanted devices can endow the material with biospecific recognition capabilities and be used in targeted drug delivery, tissue engineering and biosensor development to improve biocompatibility and functional orientation.

Conclusion

GlcNAc beta(1-3)GalNAc-alpha-Thr is not only a chemical molecule, but also a bridge connecting the frontiers of glycoscience and biomedical innovation. From decoding the basic laws of life to designing a new generation of treatments, its unique structure and application potential are constantly expanding human understanding of diseases and ability to intervene. With the rapid development of the field of carbohydrate drugs and carbohydrate vaccines, in-depth exploration of this core glycosylation unit will surely bring breakthroughs to future medicine.

The above information is provided by the editor of KASONS and is for scientific research only.